{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Liso-cel&page=2", "query": { "intervention": "Liso-cel", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Liso-cel&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-05T15:43:38.004Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07725406", "title": "Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "Relapsed or Refractory Multiple Myeloma (MM)" ], "interventions": [ { "name": "Lymphodepleting chemotherapy: Cyclophosphamide", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy: Bendamustine", "type": "DRUG" }, { "name": "Lymphodepleting chemotherapy: Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "OTHER" }, { "name": "Axicabtagene Ciloleucel", "type": "OTHER" }, { "name": "Ciltacabtagene Autoleucel", "type": "OTHER" }, { "name": "Low-Dose Total Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-08-01", "completion_date": "2033-08-31", "has_results": false, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07725406" }, { "nct_id": "NCT04359784", "title": "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2021-12-27", "completion_date": "2024-12-23", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04359784" }, { "nct_id": "NCT03331198", "title": "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, Small Lymphocytic" ], "interventions": [ { "name": "JCAR017 (lisocabtagene maraleucel)", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) + ibrutinib", "type": "BIOLOGICAL" }, { "name": "JCAR017 (lisocabtagene maraleucel) + venetoclax", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2017-11-27", "completion_date": "2027-11-26", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 83, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03331198" }, { "nct_id": "NCT03483103", "title": "Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Nonhodgkin", "Lymphoma, B-Cell", "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "lisocabtagene maraleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, a Subsidiary of Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2018-07-27", "completion_date": "2022-12-01", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 59, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 19 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03483103" }, { "nct_id": "NCT05633615", "title": "Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "Grade 3b Follicular Lymphoma", "Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Transformed Follic Lymph to Diff Large B-Cell Lymphoma", "Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma" ], "interventions": [ { "name": "Axicabtagene Ciloleucel", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Mosunetuzumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Tisagenlecleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2023-06-12", "completion_date": "2030-06-30", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 87, "location_summary": "Tucson, Arizona • Fayetteville, Arkansas • Little Rock, Arkansas + 67 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05633615" }, { "nct_id": "NCT05075603", "title": "Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Diffuse Large B-cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "High-grade B-cell Lymphoma", "DLBCL Arising From Follicular Lymphoma", "Primary Mediastinal Large B-cell Lymphoma" ], "interventions": [ { "name": "Efineptakin alfa", "type": "DRUG" }, { "name": "Tisagenlecleucel", "type": "DRUG" }, { "name": "Axicabtagene ciloleucel", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NeoImmuneTech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-07-29", "completion_date": "2025-03-12", "has_results": true, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 3, "location_summary": "Duarte, California • St Louis, Missouri • Durham, North Carolina", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05075603" }, { "nct_id": "NCT06788639", "title": "A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)", "Small Lymphocytic Lymphoma (SLL)" ], "interventions": [ { "name": "Lisocabtagene maraleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2025-02-04", "completion_date": "2044-06-30", "has_results": false, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788639" }, { "nct_id": "NCT07194980", "title": "Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Nemtabrutinib", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-09-01", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07194980" }, { "nct_id": "NCT05664217", "title": "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Hodgkin Lymphoma", "Relapsed/Refractory Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "NKTR-255 at 1.5 µg/kg", "type": "DRUG" }, { "name": "NKTR-255 at 3.0 μg/kg", "type": "DRUG" }, { "name": "NKTR-255 at 3.0/6.0 μg/kg", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2022-12-23", "completion_date": "2024-08-16", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 22, "location_summary": "La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT05664217" }, { "nct_id": "NCT05359211", "title": "NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma", "Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Polymer-conjugated IL-15 Receptor Agonist NKTR-255", "type": "DRUG" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2022-12-08", "completion_date": "2026-09-04", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-09-05T15:43:38.004Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05359211" } ] }